Exane Derivatives’s Madrigal Pharmaceuticals MDGL Stock Holding History

Exane Derivatives’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$122K	Hold	1,707	–	–	0.07%	245
2022 Q1	$167K	Sell	1,707 -209	-11%	-$17.6K	0.05%	381
2021 Q4	$162K	Hold	1,916	–	–	0.04%	372
2021 Q3	$153K	Buy	1,916 +498	+35%	+$43K	0.04%	458
2021 Q2	$143K	Buy	+1,418	New	+$168K	0.03%	492

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Exane Derivatives's MDGL Position: Q2 2022 in Review

Exane Derivatives held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2022 at 1,707 shares worth $122K. The position accounts for 0.07% of the portfolio, ranked #245.

Exane Derivatives first reported a position in MDGL in Q2 2021 and has held it in 5 quarters since. The position peaked at $167K in Q1 2022. 138 funds tracked by Wall St. Rank hold MDGL as of Q2 2022.

Exane Derivatives held 1,707 shares of Madrigal Pharmaceuticals worth $122K as of Q2 2022.
Exane Derivatives left its Madrigal Pharmaceuticals share count unchanged in Q2 2022.
Madrigal Pharmaceuticals made up 0.07% of Exane Derivatives's portfolio in Q2 2022, its #245 holding.
Exane Derivatives first reported a position in Madrigal Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
Exane Derivatives's Madrigal Pharmaceuticals position peaked at $167K in Q1 2022.
138 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.